Genmab A/S (GMAB) Reports FY23 DARZALEX Sales of $9.74B

• Net sales of DARZALEX^® in 2023 totaled USD 9,744 million
• Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen)

Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX^® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO^® in the U.S.), as reported by Johnson & Johnson were USD 9,744 million in 2023. Net trade sales were USD 5,277 million in the U.S. and USD 4,467 million in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to Janssen to develop, manufacture and commercialize daratumumab.

You May Also Be Interested In

• Boeing names Ryan Shedd as new SVP and controller
• Nuvectis Pharma (NVCT) files $200M mixed shelf
• Advance Auto Parts (AAP) Tops Q2 EPS by 22c; lifrs profit guidance